Gefitinib-based PROTAC 3

Target: Gefitinib-based PROTAC 3 targets mutant EGFR, including exon 19 deletion and L858R variants.

Binding site: Its gefitinib moiety binds the ATP-competitive kinase pocket of mutant EGFR.

Mechanism of action: Gefitinib-based PROTAC 3 is a VHL-recruiting EGFR degrader that links the EGFR inhibitor gefitinib to a von Hippel-Lindau ligand through a linker. The compound induces selective degradation of mutant EGFR in cellular models harboring exon 19 deletion or L858R substitutions, while showing limited degradation of wild-type EGFR under reported conditions. By converting mutant EGFR engagement into ubiquitination and proteasome-dependent protein loss, it supports studies of receptor depletion, downstream signaling durability, mutation-selective degradation, and differences between kinase inhibition and physical removal of oncogenic EGFR.

• PROTAC-Mediated EGFR Degradation: Gefitinib-based PROTAC 3 is designed to selectively degrade the Epidermal Growth Factor Receptor (EGFR) through the ubiquitin-proteasome system. This application is crucial for studying the effects of EGFR degradation on cellular signaling pathways and cancer cell proliferation, providing insights into novel therapeutic strategies.

• Targeted Degradation in Oncology Research: Utilizing Gefitinib-based PROTAC 3 enables researchers to investigate the potential of targeted protein degradation as a strategy to overcome resistance mechanisms in cancer treatments. By degrading mutant forms of EGFR, this PROTAC offers a unique approach to studying resistance pathways and developing more effective therapeutic interventions.

• Mechanistic Studies of PROTACs: Gefitinib-based PROTAC 3 serves as a valuable tool for elucidating the mechanistic aspects of PROTAC-mediated protein degradation. Researchers can explore the dynamics of PROTAC-induced ubiquitination and subsequent proteasomal degradation, contributing to the understanding of this novel modality in drug discovery.